News Sentiment

IMUX sentiment intelligence

Immunic Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 51 Balanced news tone 68 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 14.77 Week of 10 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

82/100 classification confidence.

Company focus 59

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

-0.2% over one week, +6.6% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

abrdn discloses 6.05% Immunic (IMUX) stake held for clients

Market Reaction

Balanced read

50/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 82/100 classification
One-week reaction -0.2% Price digesting
Trend fit Trend active 6.6% over four weeks
Fair value 27.8% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 6
Neutral 61
Negative 1

Relevance

Why the article matched

Direct first
Direct company coverage 59
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 17
TradingView 10
Market source 6
PR Newswire 5
Proactive 3
ad-hoc-news.de 2
Finviz 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 42
Earnings 18
Regulatory and legal 3
Deals and strategy 2
Balance sheet 2
Analyst action 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 68
Stock Titan Direct company coverage

abrdn discloses 6.05% Immunic (IMUX) stake held for clients

abrdn Group plc and its subsidiary abrdn Inc. have disclosed a beneficial ownership of 824,393 shares of Immunic, Inc. (IMUX) common stock, representing 6.05% of the outstanding class. This ownership is held on behalf of their clients, with shared voting and dispositive power. Th

Tone
Neutral 50/100
Event
Deals and strategy
Published
16 Jul 2026 10:11
Source
Stock Titan
TradingView Direct company coverage

Immunic posts updated corporate presentation under Regulation FD

Immunic (IMUX) has made an updated investor presentation available on its website, filed as Exhibit 99.1 to its Form 8-K on July 14, 2026. This presentation, furnished under Regulation FD, includes forward-looking statements regarding the company's development programs, clinical

Tone
Neutral 50/100
Event
Market update
Published
14 Jul 2026 11:41
Source
TradingView
Stock Titan Direct company coverage

Immunic (NASDAQ: IMUX) releases new presentation on pipeline and plans

Immunic, Inc. (NASDAQ: IMUX) released an updated corporate presentation on July 14, 2026, accessible on its website and filed as Exhibit 99.1. This presentation includes forward-looking statements regarding the company's strategy, cash runway, clinical development for vidofludimu

Tone
Neutral 50/100
Event
Balance sheet
Published
14 Jul 2026 11:41
Source
Stock Titan
MarketBeat Direct company coverage

Immunic (IMUX) Short Interest & Short Float | Updated Jul 2026

This article provides an updated overview of Immunic (IMUX) short interest and related metrics as of June 30, 2026. Immunic had 1.59 million shares sold short, representing 12.33% of its public float, marking a 2.65% decrease from the previous report. The short interest ratio is

Tone
Neutral 50/100
Event
Market update
Published
11 Jul 2026 06:44
Source
MarketBeat
Investing.com Nigeria Direct company coverage

Form 4 Immunic Inc For: 7 July By Investing.com

This article reports on a Form 4 filing for Immunic Inc. on July 7, 2026. Form 4 filings are used to declare changes in beneficial ownership of securities by a company's directors, officers, or beneficial owners. The content includes Immunic Inc.'s stock symbol (IMUX) and its cur

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 05:09
Source
Investing.com Nigeria
The Globe and Mail Direct company coverage

Immunic Names CEO Erik Lundgren to Board

Immunic announced that its CEO, Erik Lundgren, has been appointed as a Class II director to its Board, effective July 5, 2026. This appointment follows the resignation of director Tamar Howson, who retired on June 29, 2026, with no disagreements cited. Lundgren will not receive a

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 20:41
Source
The Globe and Mail
Stock Titan Direct company coverage

IMMUNIC (IMUX) director Barclay Phillips awarded 25,370 stock options as equity pay

IMMUNIC, INC. director Barclay A. Phillips was awarded 25,370 stock options as equity compensation. These options have an exercise price of $14.80 per share, expire on July 5, 2036, and will vest in monthly increments over one year. Following this grant, Phillips directly holds 2

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 19:41
Source
Stock Titan
Stock Titan Direct company coverage

IMMUNIC (IMUX) director receives 25,370 stock options at $14.80 strike price

IMMUNIC (IMUX) director Joerg Neermann was granted 25,370 stock options with an exercise price of $14.80 per share. These options will vest monthly over one year from the grant date of July 5, 2026, and will expire on July 5, 2036. This transaction was reported in an SEC Form 4 f

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Immunic director granted options for 25,370 shares | IMUX Insider Trading

Immunic, Inc. director Richard Alan Rudick was granted stock options for 25,370 shares as equity compensation. The options have an exercise price of $14.80 per share, vest monthly over one year, and expire on July 5, 2036. Following this grant, Rudick directly holds 25,370 deriva

Tone
Neutral 50/100
Event
Market update
Published
07 Jul 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Immunic (IMUX) director Jon Congleton granted 25,370 stock options at $14.80

Immunic, Inc. director Jon Congleton was granted 25,370 stock options at an exercise price of $14.80 per share, with the options vesting monthly over one year and expiring on July 5, 2036. This transaction, categorized as a grant/award acquisition, was reported on a Form 4 filing

Tone
Neutral 50/100
Event
Deals and strategy
Published
07 Jul 2026 19:39
Source
Stock Titan
Stock Titan Direct company coverage

Immunic (IMUX) CEO Erik Lundgren appointed to Board as Tamar Howson retires

Immunic, Inc. announced a change to its Board of Directors following the retirement of Tamar Howson. She resigned from the Board and its Compensation Committee on June 29, 2026. Subsequently, on July 5, 2026, the Board appointed CEO Erik Lundgren as a Class II director to serve u

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 20:10
Source
Stock Titan
Finviz Direct company coverage

IMUX - Immunic Inc Options

This Finviz page provides a detailed financial overview of Immunic Inc (IMUX), including its last closing price, market capitalization, key financial ratios, earnings per share, and stock performance metrics. It lists crucial data such as insider and institutional ownership, shor

Tone
Neutral 50/100
Event
Earnings
Published
06 Jul 2026 18:10
Source
Finviz
Finviz Direct company coverage

IMUX - Immunic Inc Latest SEC Filings

This article provides the latest SEC filings and comprehensive financial data for Immunic Inc (IMUX). It includes various financial metrics, stock performance, insider and institutional ownership, analyst recommendations, and key valuation ratios. The data indicates recent stock

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 16:12
Source
Finviz
Stock Titan Direct company coverage

IMUX SEC Filings - Immunic Inc 10-K, 10-Q, 8-K Forms

This article provides details of recent SEC filings for Immunic Inc. (IMUX), a biotechnology company. It highlights several insider stock option grants to directors and executives on June 29, 2026, including details on the number of shares, exercise prices, vesting schedules, and

Tone
Neutral 50/100
Event
Market update
Published
30 Jun 2026 14:40
Source
Stock Titan
Investing.com Australia Direct company coverage

Form 4 Immunic Inc For: 29 June By Investing.com

This article provides a Form 4 filing for Immunic Inc. as of June 29, referencing the stock ticker IMUX. It is a brief announcement indicating the availability of a regulatory filing related to insider transactions for the company. The article includes various financial market da

Tone
Neutral 50/100
Event
Regulatory and legal
Published
30 Jun 2026 11:40
Source
Investing.com Australia
Stock Titan Direct company coverage

Immunic (IMUX) director receives 25,370 fully vested options

Immunic, Inc. director Simona Skerjanec was granted 25,370 stock options with an exercise price of $10.90 per share, fully vested as of March 27, 2026. The approval of these options was contingent on stockholder approval of an amendment to the company's 2019 Omnibus Equity Incent

Tone
Neutral 50/100
Event
Regulatory and legal
Published
30 Jun 2026 01:40
Source
Stock Titan
Stock Titan Direct company coverage

Immunic (IMUX) director Neermann receives fully vested options on 25,370 shares

Immunic (IMUX) director Joerg Neermann was granted 25,370 stock options with an exercise price of $10.90 per share, fully vested as of March 27, 2026. This grant was conditional on stockholder approval of an amendment to the 2019 Omnibus Equity Incentive Plan, which occurred on J

Tone
Neutral 50/100
Event
Regulatory and legal
Published
30 Jun 2026 01:40
Source
Stock Titan
Stock Titan Direct company coverage

Immunic (IMUX) investors boost equity pool and reelect directors at 2026 meeting

Immunic, Inc. stockholders approved an amendment to the 2019 Omnibus Equity Incentive Plan, increasing authorized shares for issuance by 6,000,000 to a total of 8,644,887 common shares. This expansion provides more equity for employee and director awards. Additionally, three Clas

Tone
Neutral 50/100
Event
Market update
Published
29 Jun 2026 19:39
Source
Stock Titan
www.marketscreener.com Direct company coverage

Immunic, Inc.(NasdaqCM: IMUX) added to Russell 3000E Value Benchmark

Immunic, Inc. (NasdaqCM: IMUX), a biotechnology company specializing in oral immunology therapies, has been added to the Russell 3000E Value Benchmark. The article highlights Immunic's clinical pipeline, including its IMU-838 program in Phase III development for multiple sclerosi

Tone
Positive 65/100
Event
Market update
Published
29 Jun 2026 14:13
Source
www.marketscreener.com
TradingView Direct company coverage

Price to earnings forward of Immunic, Inc. – NASDAQ:IMUX

This article displays the "Price to earnings forward" financial metric for Immunic, Inc. (NASDAQ: IMUX). The content indicates "No trades" and "Market closed," suggesting a lack of recent trading activity or data points for this specific financial ratio. The page provides a gener

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 14:39
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Immunic, Inc. – BOATS:IMUX

This article provides financial information for Immunic, Inc. (IMUX), specifically focusing on its forward price-to-earnings ratio. It indicates that the market was closed with no trades recorded at the time of publication. The content also mentions the various data providers for

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 07:40
Source
TradingView